ReviewClinical & translational immunology2023
Roadmap for understanding mechanisms on how Epstein-Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials.
Review in Clinical & translational immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Multiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Epitope spreading in multiple sclerosis is shaped by the spatial organisation of immune responses.Frontiers in immunology · 2026Review
- The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis.Brain : a journal of neurology · 2025Review
- Multiple sclerosis and infection: history, EBV, and the search for mechanism.Microbiology and molecular biology reviews : MMBR · 2025Review
- Epstein-Barr virus and the immune microenvironment in multiple sclerosis: Insights from high-dimensional brain tissue imaging.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.Brain : a journal of neurology · 2025Article
- Multiple Sclerosis: A Virus-Induced Gliopathy?Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Epstein-Barr virus flare: A multiple sclerosis attack.Surgical neurology international · 2024Review
- From progression to progress: The future of multiple sclerosis.Journal of central nervous system disease · 2024Article
- Epstein-Barr virus and multiple sclerosis: the dawn of a new age.Clinical & translational immunology · 2023Article
- Pathogenic role of autoantibodies at the ependyma in autoimmune disorders of the central nervous system.Frontiers in cellular neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we offer a roadmap for what might be studied next in understanding how EBV triggers MS. We focus on two areas: The first area concerns the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.